Table 7.
Summary of top pathways returned by KEGG using CPDB for early- and late-stage cancer.
| Early-stage NSCLC | |||
|---|---|---|---|
| Term | Effective size | % of overlap | P value |
| Leukocyte transendothelial migration | 118 | 3.4% | 6.37E − 05 |
| Glycolysis/gluconeogenesis | 66 | 4.5% | 0.000250 |
| Epithelial cell signaling in Helicobacter pylori infection | 68 | 4.4% | 0.000273 |
| HIF-1 signaling pathway | 106 | 2.8% | 0.00100 |
| Tight junction | 134 | 2.2% | 0.00197 |
| Cell adhesion molecules (CAMs) | 147 | 2.0% | 0.00257 |
|
| |||
| Late-stage NSCLC | |||
| Term | Effective size | % of overlap | P value |
|
| |||
| Cell cycle | 124 | 9.7% | 2.39E − 12 |
| Oocyte meiosis | 110 | 7.3% | 1.38E − 07 |
| Progesterone-mediated oocyte maturation | 86 | 7.0% | 7.25E − 06 |
| DNA replication | 36 | 8.3% | 0.00100 |
| Epstein-Barr virus infection | 203 | 2.5% | 0.00512 |
| Viral carcinogenesis | 206 | 2.4% | 0.00544 |
| p53 signaling pathway | 68 | 4.4% | 0.00620 |
| Measles | 134 | 3.0% | 0.00630 |
| Hepatitis B | 146 | 2.7% | 0.00849 |